Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-label, Two-treatment, Single Period, Parallel, Single-dose, Randomized, Fasting, Lab-blinded Bioequivalence Study of Fulvestrant 50 mg/mL Versus Faslodex®, 50 mg/mL, in Healthy, Post-menopausal Female Subjects

NCT02795039 is registered in ClinicalTrials.gov with Fresenius Kabi as lead sponsor.

NCT NCT02795039
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02795039 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-label, Two-treatment, Single Period, Parallel, Single-dose, Randomized, Fasting, Lab-blinded Bioequivalence Study of Fulvestrant 50 mg/mL Versus Faslodex®, 50 mg/mL, in Healthy, Post-menopausal Female Subjects
Lead sponsor
Fresenius Kabi
Phase
Phase 1
Overall status
Completed
Start date
June 30, 2016
Completion date
March 3, 2017
Enrollment
266 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

healthy